Cerus reported it saw an increase in revenue in the fourth quarter due in part to higher sales of disposable kits used with its Intercept blood-screening system, which eliminates bacteria, viruses and parasites in donated platelets. The company said it is preparing to initiate two late-stage clinical trials involving its screening system for red blood cells.

Full Story:
CBS MoneyWatch

Related Summaries